[1-Myristoyl-glycerol-3-YL]phosphonylcholine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: [1-Myristoyl-glycerol-3-YL]phosphonylcholine
• 英文别名: 2-[hydroxy-[(2R)-2-hydroxy-3-tetradecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
• 化学式: C22H47NO7P+
• 分子量: 468.6
• InChiKey: VXUOFDJKYGDUJI-OAQYLSRUSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  22
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR IMPROVED DRUG LOADING
  申请人：Lawrence Livermore National Security, LLC

  公开号：EP3426304A1

  公开（公告）日：2019-01-16
• METHODS FOR DETECTING OR MONITORING CANCER USING LPC AS A MARKER
  申请人：Shan Lian

  公开号：US20100291690A1

  公开（公告）日：2010-11-18

  A method of detecting a cancer, such as ovarian cancer, in a test subject including (a) determining the amount of a lysophosphatidyl choline in a sample of a bodily fluid taken from the test subject, and (b) comparing the amount of the lysophosphatidyl choline in the sample of the bodily fluid taken from the test subject to a range of amounts of lysophosphatidyl choline found in samples of the bodily fluid taken from a group of normal subjects of the same species as the test subject and lacking the cancer, such as ovarian cancer, whereby a change in the amount of the lysophosphatidyl choline in the sample of the bodily fluid taken from the test subject indicates the presence of the cancer, such as ovarian cancer.
• PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES
  申请人：SignPath Pharma Inc.

  公开号：US20150343063A1

  公开（公告）日：2015-12-03

  The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. Such compositions may further comprise a monoglyceride, a free fatty acid or a combination of the foregoing, including, e.g., a eutectic mixture.
• Oral Composition for Delivery of Drugs and Other Substances
  申请人：AVANTI POLAR LIPIDS, INC.

  公开号：US20160166699A1

  公开（公告）日：2016-06-16

  The present disclosure provides for a composition which may be used for the solublization of an agent or the oral administration of an agent, the composition comprising, a lyosphosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lyosphosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lyosphosphatidyl compound, a monoglyceride and a free fatty acid.
• [EN] PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES<br/>[FR] EFFET PROTECTEUR DE DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG ET LYSOPC CONTRE DES MÉDICAMENTS PROVOQUANT DES CANALOPATHIES
  申请人：SIGNPATH PHARMA INC

  公开号：WO2015187883A1

  公开（公告）日：2015-12-10

  The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. Such compositions may further comprise a monoglyceride, a free fatty acid or a combination of the foregoing, including, e.g., a eutectic mixture.